Boston

Biotech By Rebecca Sohn

‘As good a model as I’ve seen’: MIT biologist on new initiative to address gender inequities in biotech

Hospitals By Priyanka Dayal McCluskey — Boston Globe

Massachusetts General Hospital president Peter Slavin to depart after 18 years

Biotech By Anissa Gardizy — Boston Globe

MIT scientists launch Future Founders Initiative to solve biotech’s ‘missing women’ problem

Hospitals By Liz Kowalczyk, Sarah L. Ryley, Mark Arsenault, and Patricia Wen — Boston Globe

Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level

In the Lab By Scott Kirsner — Boston Globe

The Broad Institute’s new leader wants to ‘double down’ on biology

Biotech By Adam Feuerstein and Damian Garde

FDA delays approval decision for Biogen’s Alzheimer’s treatment

Biotech By Larry Edelman — Boston Globe

After Moderna’s medical miracle, some investors step back

By Casey Ross and Erin Brodwin

‘What was left for Haven?’: How Amazon’s health ambitions devoured Haven’s plans

Biotech By Anissa Gardizy — Boston Globe

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

In the Lab By Sharon Begley

CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging

First Opinion By Shirley Leung

‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well

Biotech By Anissa Gardizy — Boston Globe

New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases

Pharmalot By Ed Silverman

Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug

Biotech By Anissa Gardizy — Boston Globe

Alnylam wins FDA approval for first drug to treat rare kidney disease

Biotech By Jonathan Saltzman — Boston Globe

A new startup wants to use natural killer cells to fight cancer

Health Tech By Casey Ross

A leading AI researcher calls for standards to ensure equity and fairness

First Opinion By Jessica Stuart

I was a ‘nonadherent’ patient. That’s made me a more empathetic doctor

A STAT Investigation By Kathleen McLaughlin

HHS relaxed oversight of problematic Covid-19 tests despite being told of accuracy concerns

Biotech By Anissa Gardizy — Boston Globe

Foghorn Therapeutics raises $120 million in IPO

Biotech By Jonathan Saltzman — Boston Globe

Disarm Therapeutics bought by Lilly for $135 million

First Opinion By Kathryn Holroyd, Neha Limaye, and Hallie Rozansky

As the second surge looms, systems issues — not ‘weary staff’ — should be the focus for hospital safety

First Opinion By Pardis Sabeti and Yolanda Botti-Lodovico

A mumps epidemic has a lot to teach colleges about reopening safely in the time of coronavirus

In the Lab By Elizabeth Cooney

‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win

Health By Eric Boodman

He’s a recruiter for a Covid-19 vaccine trial. Can he overcome communities’ distrust — and his own mother’s?

Biotech By Jonathan Saltzman — Boston Globe

Biotech looking to fight kidney disease launches with $51 million